Teleflex (TFX)
(Delayed Data from NYSE)
$239.18 USD
-0.36 (-0.15%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $239.20 +0.02 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$239.18 USD
-0.36 (-0.15%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $239.20 +0.02 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
Zacks News
Is ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSM
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.
Why Is Waters (WAT) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teleflex (TFX) Signs Peripheral Access Purchasing Deal With PINC
by Zacks Equity Research
Teleflex (TFX) secures the Peripheral Access purchasing agreement with Premier, Inc.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Teleflex (TFX) on the strength of the Vascular and Interventional businesses.
Teleflex (TFX) Enrolls First Patient in ACCESS-MANTA Registry
by Zacks Equity Research
Teleflex's (TFX) ACCESS-MANTA Registry is likely to examine the contemporary on-label use of the MANTA VCD.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Teleflex (TFX) Q3 Earnings Top Estimates, 2023 Outlook Up
by Zacks Equity Research
Teleflex's (TFX) year-over-year revenue growth was driven by all global product categories in Q3.
Compared to Estimates, Teleflex (TFX) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) to Report Q3 Results: What to Know Ahead of the Release
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teleflex (TFX) Advances Urology Portfolio With New Buyout
by Zacks Equity Research
Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX), led by growth in Vascular, Interventional and Surgical businesses.
Teleflex (TFX) Rides on Urolift Prospects Amid Cost Pressures
by Zacks Equity Research
With respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting.
Teleflex (TFX) Picked for Vizient Innovative Technology Exchange
by Zacks Equity Research
Teleflex (TFX) gets selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange.
Teleflex (TFX) New Survey Highlights BPH Impact Life Quality
by Zacks Equity Research
Teleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
A diversified product portfolio and a broad geographic footprint bode well for Teleflex (TFX).
Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System
by Zacks Equity Research
Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.
Teleflex (TFX) Q2 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Strong performances in its Vascular, Interventional and Surgical businesses drives Teleflex (TFX) Q2 revenues.
Compared to Estimates, Teleflex (TFX) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Teleflex (TFX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teleflex (TFX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 6.23% and 1.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Teleflex (TFX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Revenue growth across global product categories and a broad geographic footprint bode well for Teleflex (TFX).
Teleflex's (TFX) Urolift Global Expansion Aids Amid Cost Woes
by Zacks Equity Research
Teleflex's (TFX) vascular and interventional access product portfolios witness accelerated growth following the $976-million acquisition of Vascular Solutions.